Publications by authors named "Benjamin Shao Kiat Ong"
Impact of COVID-19 pandemic on HTAsiaLink network members.
Int J Technol Assess Health Care
November 2024
Objectives: This study investigates the impact of coronavirus disease 2019 (COVID-19) pandemic on HTAsiaLink members at the organizational level and provides recommendations for mitigating similar challenges in the future.
Methods: A survey was disseminated among HTAsiaLink members to assess the COVID-19 impact in three areas: (i) inputs, (ii) process, and (iii) outputs of the Health Technology Assessment organizations' (HTAOs) research operations and HTA process in general.
Results: Survey results showed that most HTAOs hired more staff and secured similar or higher funding levels during COVID-19.
Article Synopsis
- Healthcare sustainability is an important issue globally; in Singapore, the Agency for Care Effectiveness has implemented strategies to promote the use of biosimilars to manage rising costs in biologics.
- A study analyzed drug utilization data from public healthcare institutions, focusing on five monoclonal antibodies with biosimilars, and found significant increases in biosimilar adoption and substantial decreases in spending.
- Overall, the subsidy for biosimilars led to over 95% adoption rates within a year and estimated savings of $136 million over five years, indicating the effectiveness of these healthcare strategies.
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore.
Expert Rev Pharmacoecon Outcomes Res
February 2024
Objective: To assess the cost-effectiveness of sacituzumab govitecan for treating relapsed or refractory metastatic triple-negative breast cancer (TNBC) in Singapore.
Methods: A three-state partitioned survival model was developed to evaluate the cost-effectiveness of sacituzumab govitecan from a healthcare system perspective over 5 years. Clinical inputs were obtained from the ASCENT trial.
Background And Aim: Sofosbuvir-velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes. Specifically, we looked at pre- and post-subsidy changes in the utilization and prescribing pattern of chronic hepatitis C treatment and the real-world clinical effectiveness.
View Article and Find Full Text PDFPurpose: Sodium-glucose co-transporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors are increasingly used as second-line therapies in patients with type 2 diabetes. The aim of this study was to assess the real-world effects of SGLT2 inhibitors in a multi-ethnic population in Singapore.
Methods: This retrospective cohort study examined patients diagnosed with and treated for diabetes from the Ministry of Health's administrative database.